Home Journals Articles Updates About
CN
image
收藏切换
Valeriaquinone A, a unique anthraquinone-coumarin hybrid with selective inhibition of PTP1B from Knoxia valerianoides
收藏切换
PDF
Yan Jiang1, Ren-Yong Yang1, Zhao-Xia Qu, Gui-Ge Hou, Wei Cong, Chun-Hua Wang, Feng Zhao*
Chinese Chemical Letters | 2022, 33(6) : 2919 - 2922
Less
收藏切换
Chinese Chemical Letters | 2022, 33(6): 2919-2922
• Communication •
Valeriaquinone A, a unique anthraquinone-coumarin hybrid with selective inhibition of PTP1B from Knoxia valerianoides
Full
Yan Jiang1, Ren-Yong Yang1, Zhao-Xia Qu, Gui-Ge Hou, Wei Cong, Chun-Hua Wang, Feng Zhao*
Affiliations
  • The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, Yantai 264003, China
Published: 2022-06-15 doi: 10.1016/j.cclet.2021.10.072
Outline
收藏切换

Valeriaquinone A (1), an unprecedented anthraquinone-coumarin hybrid, was isolated from the roots of Knoxia valerianoides. Its structure was determined by extensive spectroscopic analyses and X-ray diffraction. The plausible biosynthetic pathways for 1 were proposed. Compound 1 exhibited strong protein tyrosine phosphatase 1B (PTP1B) inhibition with high selectivity (> 30 fold) over homologous T cell protein tyrosine phosphatase (TCPTP) potentially by binding to an allosteric site predicted by kinetic analysis and molecular docking. Moreover, compound 1 showed significant cytotoxic activities against three human hepatoma cell lines (HepG2, QGY-7703, and SMMC-7721) with half maximal inhibitory concentration (IC50) values of 1.39 ± 0.2, 10.34 ± 2.09, and 5.56 ± 0.47 µmol/L, respectively.

Knoxia valerianoides  /  Anthraquinone-coumarin hybrid  /  PTP1B inhibitory activity  /  Cytotoxic activity  /  Allosteric inhibition
Yan Jiang, Ren-Yong Yang, Zhao-Xia Qu, Gui-Ge Hou, Wei Cong, Chun-Hua Wang, Feng Zhao. Valeriaquinone A, a unique anthraquinone-coumarin hybrid with selective inhibition of PTP1B from Knoxia valerianoides[J]. Chinese Chemical Letters, 2022 , 33 (6) : 2919 -2922 . DOI: 10.1016/j.cclet.2021.10.072
Full Text
Less
Natural anthraquinones comprise an important class of secondary metabolites with a 9, 10-anthracenedione core derived from polyketides or chorismate/o-succinylbenzoic acid [1, 2], and show a range of biological activities such as anticancer, laxative, anti-inflammatory, antibacterial, and hypoglycemic activities [3-5]. Their structural diversity mainly originates from biological oxidation and glycosylation of the benzene rings, and homodimerization of monomeric subunits [3]. Fewer anthraquinone derivatives are characterized by anthraquinone-xanthone heterodimers [6-8], and anthraquinone-based antibiotics [9-13]. Natural coumarins are a large group of heterocyclic compounds exhibiting versatile bioactivities, and most of them represent 7-hydroxycoumarin derivatives with various substitutions and conjugations, as well as regioisomeric dimers [14]. The benzo-α-pyrone motif of coumarin has also been demonstrated to be a unique pharmacophore in medicinal chemistry [15, 16].
Knoxia valerianoides Thorel ex Pitard (Rubiaceae) is a perennial plant distributed in the southern regions of China. Its roots are used in traditional Chinese medicine as purgative and anti-ulcer agents. Our previous study on this plant led to the isolation of an array of Rubia type anthraquinones and pentacyclic triterpenoids, two lignans and a coumarin, and some of them showed antiviral, anti-inflammatory, and hepatoprotective activities [17-19]. As part of our continuous research, further investigation on K. valerianoides resulted in the identification of an unprecedented anthraquinone-coumarin hybrid, valeriaquinone A (1) (Fig. 1). Herein, we describe the isolation, structure elucidation, proposed biosynthetic pathways, and bioassay of 1.
Valeriaquinone A (1) was initially obtained as an orange-yellow solid, and its molecular formula was determined as C25H16O9 by high resolution electrospray ionization mass spectroscopy (HRESIMS) ion at m/z 459.0710 [M-H]− (calcd. for 459.0722) combined with 1H and 13C nuclear magnetic resonance (NMR) spectroscopic data (Table 1), accounting for 18 degrees of unsaturation. Compound 1 showed UV/vis absorption maxima (CH3OH) at 204, 239, 281, 336, and 407 nm that were similar to those for previously obtained hydroxyanthraquinones [17, 18]. The infrared spectroscopy (IR) spectrum displayed absorption bands for hydroxyl (3743 and 3304 cm−1), conjugated carbonyl (1663 cm−1), and aromatic ring (1590 and 1512 cm−1) groups. The 13C NMR, distortionless enhancement by polarization transfer (DEPT), and 1H-detected heteronuclear single quantum coherence spectroscopy (HSQC) spectra showed a total of 25 carbon signals assignable to two carbonyls at δC 186.8 and 182.4 typical for an anthraquinone scaffold, 21 sp2-hybridized carbons (ranging from δC 100.3 to 163.9) including 7 methines and 14 nonprotonated carbons, a methoxyl (δC 56.3), and an aliphatic methylene group (δC 23.4). The 1H NMR spectrum showed resonances for four downfield shifted aromatic protons [δH 7.93 (ddd, J = 7.0, 7.0, 1.75 Hz), 7.95 (ddd, J = 7.0, 7.0, 1.95 Hz), 8.19 (dd, J = 7.0, 1.75 Hz), and 8.24 (dd, J = 7.0, 1.95 Hz)] attributable to an ortho-disubstituted benzene ring, a singlet aromatic proton (δH 7.37, s), and a hydrogen-bonded phenolic hydroxyl (δH 13.18, s). The aforementioned data indicated a 1, 2, 3-trisubstituted anthraquinone subunit for 1, and that the hydroxyl (δH 13.18) was located at C-1. This fragment was corroborated by 1H-1H correlation spectroscopy (COSY) correlations of H-5/H-6/H-7/H-8, and heteronuclear multiple bond correlation spectroscopy (HMBC) correlations from H-4 (δH 7.37) to C-2 (δC 117.7), C-3 (δC 163.9), and C-10 (δC 182.4), from H-5 (δH 8.19) to C-10, from H-8 (δH 8.24) to C-9 (δC 186.8), and from 1-OH to C-1 (δC 163.3), C-2, and C-9a (δC 109.8) (Fig. 2). The hydroxyl (δH 11.47) was affixed to C-3 based on the downfield chemical shift of C-3 (δC 163.9) combined with nuclear overhauser effect spectroscopy (NOESY) correlations of OH-3/H-4. HMBC correlations of methylene protons (δH 3.77) with C-1, C-2, and C-3 confirmed the attachment of the methylene group to C-2.
Additionally, 1H NMR spectrum showed 4JH, H couplings (J = 1.5 Hz) between H2-11 and H-4′ (δH 7.18), indicating the presence of an allylic residue in 1 (Fig. 2 and Fig. S5 in Supporting information), which was in agreement with the observed 1H-1H COSY and NOESY cross-peaks of H2-11/H-4′. The downfield shift of olefinic proton H-4′ (δH 7.18) suggested that a carbonyl group (C-2′) was connected to the double bond (C-3′=CH-4′). HMBC correlations from H2-11 to C-2′ (δC 161.8), C-3′ (δC 121.9) and C-4′ (δC 139.0), and from H-4′ to C-11 (δC 23.4), C-2′, and C-3′ verified the linkages of CH2-11−C-3′ and C-2′−C-3′=CH-4′. Considering the degrees of unsaturation, the proton signal at δH 6.68 (H-5′, s) was attributable to a pentasubstituted benzene ring, as evidenced by the HMBC correlations of H-5′/C-6′, C-7′, C-9′ and C-10′, OH-7′/C-6′, C-7′ and C-8′, and OH-8′/C-7′ and C-8′. The methoxy (δH 3.70) was placed at C-6′ based on the HMBC correlation of OCH3/C-6′ and NOESY correlations of OCH3/H-5′. The connection of C-4′−C-10′ was disclosed by HMBC correlations of H-4′/C-5′, C-9′, and C-10′, and NOESY correlations of H-4′/H-5′ (Fig. 2).
Apart from the above residues, an additional ring and an oxygen atom are required to satisfy the hydrogen deficiency and molecular formula, respectively. Thus, the carbonyl (C-2′) and C-9′ were proposed to be connected through an oxygen atom, forming a lactone ring, which was consistent with the quaternary carbon of C-9′ (δC 138.4) and the obvious upfield chemical shift of C-2′ (δC 161.8). The structure of 1 was further determined by X-ray diffraction analysis using Cu Kα radiation (Fig. 3, CCDC 1471733). Compound 1 is optically inactive and displayed no optical rotation values or Cotton effects.
The plausible biosynthetic pathways are proposed in Scheme 1. The biosynthetic precursors of 1 are traced to lucidin (2) and scopoletin (3). Lucidin is the major component from the title plant and shares the same substitution pattern as that of the anthraquinone moiety of 1. Only a furanocoumarin, cnidilin, was obtained from K. valerianoides [19], thus the 7-hydoxrycoumarin derivative, scopoletin, was proposed to be another precursor. Briefly, dehydration of 2 could produce intermediate i. Then, a conjugate addition of i with 3 could yield ii [20], which undergoes further oxidation to afford 1 (Scheme 1A). Alternatively, the biosynthesis might involve a free radical coupling reaction (Scheme 1B). Scopoletin (3) is still presumed to be a precursor. 3 undergoes initial oxidation through hydrogen atom abstraction from the 7′-OH to form a free radical intermediate iii. The free radical at 7′-O in iii migrates to C-3′ to produce radical iv [21], which suffers a radical coupling with the benzylic radical intermediate v generated in the oxidation process of anthraquinone precursor vi to form ii.
Furthermore, we attempted to perform the coupling reaction using 2 and 3 under reflux condition in methanol, or by reaction of the two subunits of 1, fraxetin and co-isolated rubiadin, using Cu(OAC)2 as a catalyst and tert‑butylperoxy benzoate as the oxidant [22]. An additional strategy based on the formation of the methylene bridge in dicoumarol [23] was also developed by reaction of fraxetin and co-isolated xanthopurpuin with formaldehyde under mild conditions. All the above attempts turned out to be fruitless providing partial evidences for the natural occurrence of 1.
The protein tyrosine phosphatase (PTP) 1B negatively regulates insulin signaling pathway through dephosphorylation of the insulin receptor and is highly validated as a therapeutic target for type 2 diabetes [24]. Moreover, PTP1B is also implicated in a variety of disorders, including cancer [25], inflammation [26], and cardiovascular diseases [27]. However, due to the charged catalytic site that is conserved among all PTPs, the designed phosphotyrosine mimetics suffer from poor selectivity and bioavailability, and none of them has as yet successfully passed the clinical trials. The hydrophobic and less conserved allosteric sites are demonstrated to be unique alternative targets for developing selective and cell-permeable PTP1B inhibitors [28, 29]. In vitro bioassays revealed that compound 1 showed significant inhibitory effect on PTP1B activity with an half maximal inhibitory concentration (IC50) value of 2.42 µmol/L. Notably, compound 1 exhibited 30.3-fold selectivity for PTP1B over the homologous phosphatase T cell protein tyrosine phosphatase (TCPTP) which shares 75% sequence identity with PTP1B in the catalytic domain (Table S1 in Supporting information). Further kinetic analysis and molecular docking were performed to elucidate the selective inhibition. Dixon-plot of the kinetic data showed intersecting lines in the xy region, revealing mixed-type inhibition of PTP1B with a K value of 0.96 µmol/L (Fig. 4 and Fig. S1 in Supporting information), which implied an allosteric mechanism of inhibition. Docking results indicated that compound 1 binds to the catalytic site and an allosteric site formed by helices α3 and α6. The latter complex conformation has lower binding energy and shows a binding mode similar to that of the reported benzofuran derivatives [28]. As shown in Fig. 4B, Compound 1 embeds the coumarin moiety in the hydrophobic pocket, and wraps around the central position Phe280 that is not conserved and replaced by cysteine in TCPTP. Strong π-π interactions between the rigid aromatic nucleus with Phe280, and hydrogen bonds with Asn193 and Glu276 were formed. Additional π-alkyl interactions with Leu192, Ala189 and Met282 were probably formed to enhance the binding potency of 1. The docking results agreed with kinetic analysis and suggested the ability of 1 to block the interactions between helices α3-α6-α7 and trap PTP1B in the inactive conformation, which might account for its potency and selectivity for PTP1B (detailed in silico docking results were depicted in Figs. S2 and S3, and Table S2 in Supporting information.
Compound 1 was also evaluated for its cytotoxicity [30], and the results indicated that 1 exhibited cytotoxic activities against human hepatoma HepG2, QGY-7703 and SMMC-7721 cell lines with IC50 values of 1.39 ± 0.2, 10.34 ± 2.09, and 5.56 ± 0.47 µmol/L, respectively, and had no significant effect on human lung adenocarcinoma A549 cells up to the concentration of 50 µmol/L (Table S3 in Supporting information).
In conclusion, valeriaquinone A (1), a unique anthraquinone-coumarin hybrid, was isolated from the roots of K. valerianoides. The biosynthesis might involve a conjugate addition, or an alternative radical coupling reaction. Compound 1 showed selective PTP1B inhibition and was predicted to be an allosteric inhibitor based on kinetic analyses and molecular docking. Meanwhile, compound 1 showed significant cytotoxic activities. The characterization of 1 enriches the diversity of anthraquinone-, and coumarin-based dimers, and provides a template for development of novel selective PTP1B inhibitors.
Declaration of competing interest
Less
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
Less
This work was financially supported by National Natural Science Foundation of China (No. 81703391), Shandong Provincial Natural Science Foundation of China (No. ZR2020KB015), and Key R & D Program of Shandong Province (No. 2019JZZY011104, China).
Supplementary materials
Less
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2021.10.072
References
Less
[1]
G. Bringmann, A. Irmer, D. Feineis, et al., Phytochemistry 70 (2009) 1776-1786.
[2]
Y.S. Han, R. Van der Heijden, R. Verpoorte, Plant Cell Tissue Organ Cult. 67 (2001) 201-220.
[3]
Y. Li, J.G. Jiang, Food Funct. 9 (2018) 6063-6080.
[4]
É. S. Almeida, D. de Oliveira, D. Hotza, Compr. Rev. Food Sci. Food. 18 (2019) 883-909.
[5]
E.M. Malik, C.E. Müller, Med. Res. Rev. 36 (2016) 705-748.
[6]
S.D. Holmbo, S.V. Pronin, J. Am. Chem. Soc. 140 (2018) 5065-5068.
[7]
C. Tantapakul, T. Promgool, K. Kanokmedhakul, et al., Nat. Prod. Res. 34 (2020) 494-502.
[8]
G.D. Anaya-Eugenio, D. Rebollar-Ramos, M. del Carmen González, et al., Chem. Biol. Interact. 311 (2019) 108798.
[9]
J.W. Lown, Pharmacol. Ther. 60 (1993) 185-214.
[10]
K.C. Nicolaou, Q. Cai, H. Sun, et al., J. Am. Chem. Soc. 138 (2016) 3118-3124.
[11]
M.K. Kharel, P. Pahari, M.D. Shepherd, et al., Nat. Prod. Rep. 29 (2012) 264-325.
[12]
Z. Wang, Z. Wen, L. Liu, et al., J. Nat. Prod. 82 (2019) 2483-2488.
[13]
K.C. Nicolaou, D. Das, Y. Lu, et al., J. Am. Chem. Soc. 142 (2020) 2549-2561.
[14]
H. Hussain, J. Hussain, A. Al-Harrasi, et al., Tetrahedron 68 (2012) 2553-2578.
[15]
F.G. Medina, J.G. Marrero, M. Macías-Alonso, et al., Nat. Prod. Rep. 32 (2015) 1472-1507.
[16]
I. Fotopoulos, D. Hadjipavlou-Litina, Med. Chem. 16 (2019) 272-306.
[17]
F. Zhao, S. Zhao, J.T. Han, et al., Phytochem. Lett. 11 (2015) 57-60.
[18]
F. Zhao, S. Wang, S. Lin, et al., Acta Pharm. Sin. B 2 (2012) 260-266.
[19]
F. Zhao, S. Wang, X. Wu, et al., Chin. J. Chin. Mater. Med. 37 (2012) 2092-2099.
[20]
W. Wang, X. Tang, F. Hua, et al., Org. Lett. 20 (2018) 2672-2675.
[21]
B. Zhao, F.P. Guengerich, A. Bellamine, et al., J. Biol. Chem. 280 (2005) 11599-11607.
[22]
S.L. Zhou, L.N. Guo, X.H. Duan, Eur. J. Org. Chem. 2014 (2014) 8094-8100.
[23]
M.S. Spring, J.R. Stoker, Can. J. Biochem. 46 (1968) 1247-1251.
[24]
Y. Tang, X. Zhang, Z. Chen, et al., Acta Pharm. Sin. B 8 (2018) 919-932.
[25]
R.S. Banh, C. Iorio, R. Marcotte, et al., Nat. Cell Biol. 18 (2016) 803-813.
[26]
L. Yang, Y.Y. Sun, Y.R. Liu, et al., Toxicol. Lett. 319 (2020) 11-21.
[27]
P.A. Thiebaut, M. Besnier, E. Gomez, et al., J. Mol. Cell. Cardiol. 101 (2016) 50-57.
[28]
C. Wiesmann, K.J. Barr, J. Kung, et al., Nat. Struct. Mol. Biol. 11 (2004) 730-737.
[29]
N. Krishnan, D. Koveal, D.H. Miller, et al., Nat. Chem. Biol. 10 (2014) 558-566.
[30]
Z. Qu, L. Ma, Q. Zhang, et al., Acta Crystallogr. C Struct. Chem. 76 (2020) 269-275.
Appendix
Less
Year 2022 volume 33 Issue 6
PDF
58
32
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2021.10.072
  • Receive Date：2021-09-05
  • Online Date：2025-12-19
  • Published：2022-06-15
Article Data
Affiliations
History
  • Received：2021-09-05
  • Revised：2021-10-12
  • Accepted：2021-10-25
Affiliations
    The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine, School of Pharmacy, Binzhou Medical University, Yantai 264003, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2021.10.072
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House